Early pregnancy-abortion model using sulprostone.
Sulprostone has been demonstrated to be effective as a parenteral abortifacient, but not as a vaginal suppository. A vaginal preparation was given to 19 women to determine its mechanism of action, and to confirm the principle of uterine conversion as a biological model for the induction of an early abortion. The drug was administered to women with confirmed pregnancies and amenorrhea and not exceeding 49 days. A 95% success rate was obtained with an incidence of drug related side effects of 20% as opposed to the general 80-90% figure of PGE2 and F2a. The hormone profile obtained revealed a parallel fall in hCG and estradiol, and progesterone. This study confirms the value of uterine conversion, a concept that describes the change in uterine reactivity following PG administration and determines the phase when uterine activity is no longer dependent on exogenous oxytocic medication.
D000028:Abortion, Induced; D055598:Chemical Phenomena; D002621:Chemistry; D006063:Chorionic Gonadotropin / Q000097:blood; D015232:Dinoprostone / Q000031:analogs & derivatives*; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011374:Progesterone / Q000097:blood; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D013488:Suppositories; D014590:Uterine Contraction / Q000187:drug effects; D014621:Vagina
D006063:Chorionic Gonadotropin; D011459:Prostaglandins E, Synthetic; D013488:Suppositories; D011374:Progesterone; D004958:Estradiol; C016767:sulprostone; D015232:Dinoprostone